Todays approval in the frontline consolidation phase, regardless of MRD status, allows us to reach more patients than ever with this transformative, first-in-class Bispecific T-cell Engager (BiTE) therapy, Jay Bradner, executive vice president of research and development and chief scientific officer at Amgen, said in a press release
Five of the cases occurred in individuals taking semaglutide, while five of the cases occurred in individuals taking tirzepatide
Switching within drug classes Switching from one GLP-1 to another , such as moving from semaglutide to tirzepatide, is a different kind of transition entirely
This glucose-lowering effect has a low intrinsic risk of hypoglycemia, though the risk increases when combined with insulin or sulfonylureas
Review the evidence before relying on the site
This simple step costs nothing and takes barely a minute, yet most people skip it